HomeCannabisZynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global...

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

Published on

DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) —

Zynerba Pharmaceuticals

, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24

th

Annual Global Investment Conference on Tuesday, September 13, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace Hotel in New York City.

Investors interested in arranging an in-person meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. An archived webcast of the presentation will be available on-demand for 60 days following the event under the

Events & Webcasts

tab of the Investors section of the Zynerba website at

www.zynerba.com

.


About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum disorder. Learn more at

www.zynerba.com

and follow us on Twitter at @ZynerbaPharma.


Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, incentive and other tax credit eligibility, collectability and timing, and availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company’s product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration, the European Medicines Agency and other foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company’s reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the extent to which health epidemics and other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions; and the extent to which inflation or global instability, including political instability, may disrupt our business operations or our financial condition. This list is not exhaustive and these and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Zynerba Contacts

Peter Vozzo

ICR Westwicke

Office: 443.213.0505

Cell: 443.377.4767


[email protected]

ti?nf=ODYzOTcyMyM1MTMzNDEwIzIwMTcyOTU= Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference


Primary Logo

Featured image: Megapixl © Jetacomputer

Disclaimer

Latest News

CNBX Peer-reviewed Study: “Possible Future Therapeutic Value” for CNBX Proprietary Drug Candidate

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for...

Heritage Cannabis Announces Second Amendment to Senior Secured Loan and a Facility Increase to $19.775 Million

Toronto, ON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Heritage...

Grown Rogue Reports Third Quarter 2022 Results, Positive Free Cash Flow and Net Income

Grown Rogue Reports Third Quarter 2022 Results, Positive...

FIRST-EVER TOM’S OF MAINE INCUBATOR TO ELEVATE NEXT GENERATION OF BIPOC ENVIRONMENTAL LEADERS

FIRST-EVER TOM'S OF MAINE INCUBATOR TO ELEVATE NEXT...

More like this

Canopy Growth Announces Divestiture of Canadian Retail Operations

Canopy Growth Announces Divestiture of Canadian Retail Operations ...

CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation

CV Sciences, Inc. Announces Proposed Settlement of Shareholder...

ePlus Achieves Palo Alto Networks Authorized Support Center Certified Partner Status

ePlus Achieves Palo Alto Networks Authorized Support Center...

SweetWater Brewing Company Unveils New Fall Craft-Beer Releases

SweetWater Launches New IPA Variety 12-Pack, Introduces New H.A.Z.Y Double IPA and Brings Back...

Cannabis companies are thriving as a result of Europe’s call for medical marijuana

A South African manufacturer has sold all of its output for the upcoming year...